On February 21, 2023 GlyTherix Ltd, an Australian immuno-oncology company specialising in developing antibody radiopharmaceuticals for solid tumors, reported that it has executed an agreement with the Australian Nuclear Science and Technology Organisation (ANSTO) in Sydney to supply the Company with isotope non-carrier-added Lutetium-177 (177Lu) for its planned Phase 1b trials in Australia (Press release, Glytherix, FEB 21, 2023, View Source [SID1234627440]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The isotope will be used in combination with GlyTherix’s proprietary antibody, Miltuximab, targeting tumours expressing Glypican-1 in a Phase Ib imaging and therapeutic dose escalation trial.
Glypican-1 is expressed in a number of aggressive and invasive cancers including prostate, pancreatic, bladder, lung, glioblastoma and ovarian cancer. An antibody labelled with 89-Zirconium will be used as an imaging agent to select patients showing tumour targeting, followed by a therapeutic dose of 177Lu-Miltuximab being offered to qualifying patients.
The basket trial is planned to start in late 2023 in collaboration with ANSTO.
Chief Executive Officer of GlyTherix Ltd, Dr Brad Walsh said partnering with ANSTO will place Glytherix on the right path to initiating medical trials in Australia.
"Lutetium has shown good anti-cancer efficacy with other molecular targeted therapies and we are confident this will be the case with Miltuximab," Dr Walsh said.
"The growing demand for high-quality lutetium has driven us to strengthen our current relationship with ANSTO as one of the premier suppliers of this isotope."
Chief Executive Officer of ANSTO, Shaun Jenkinson welcomed the agreement as an opportunity to expand ANSTO’s commitment to providing outcomes for human health.
"One of ANSTO’s core missions is to advance the use of radiopharmaceuticals to benefit the health of Australians and help save lives," Mr Jenkinson said.
"Globally, there is a growing clinical interest in new therapeutic radiopharmaceuticals, and through the work of ANSTO, Australia is already a world leader in the advanced manufacturing of diagnostic and therapeutic nuclear medicines to help treat current and emerging diseases."
Media contacts:
GlyTherix Ltd: Dr Brad Walsh, [email protected], 0413 231 296
ANSTO: Melissa Richardson, [email protected], 0499 830 165